相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
Hyun Jee Han et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells
Chi Zhang et al.
LIFE SCIENCES (2021)
Dendritic Cell-Based Immunotherapy in Lung Cancer
Dieter Stevens et al.
FRONTIERS IN IMMUNOLOGY (2021)
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
Xiaoping Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells
Maxine Umeh-Garcia et al.
CANCER RESEARCH (2020)
Designer nanocarriers for navigating the systemic delivery of oncolytic viruses
Faith Howard et al.
NANOMEDICINE (2020)
RNA-based pharmacotherapy for tumors: From bench to clinic and back
Xiangping Liang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Proliferation-associated long noncoding RNA,TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer
Yuichi Mitobe et al.
CANCER SCIENCE (2020)
A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.
Manish R. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery
Yulia Eygeris et al.
NANO LETTERS (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Delivery and Biosafety of Oncolytic Virotherapy
Lizhi Li et al.
FRONTIERS IN ONCOLOGY (2020)
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
Zhen Zhao et al.
SCIENCE ADVANCES (2020)
ADAM9 Mediates Triple-Negative Breast Cancer Progression via AKT/NF-κB Pathway
Rui Zhou et al.
FRONTIERS IN MEDICINE (2020)
Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Sundee Dees et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy
Ayeskanta Mohanty et al.
MOLECULES (2020)
LGR6 Promotes Tumor Proliferation and Metastasis through Wnt/β-Catenin Signaling in Triple-Negative Breast Cancer
Yanan Kong et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside
Muhammad Imran Sajid et al.
PHARMACEUTICALS (2020)
Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease
Amal Qattan
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review
Simona Ruxandra Volovat et al.
FRONTIERS IN ONCOLOGY (2020)
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype
Andrea Angius et al.
CANCERS (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy
Amita M. Vaidya et al.
BIOCONJUGATE CHEMISTRY (2019)
Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis
Divya Ramchandani et al.
MOLECULAR CANCER THERAPEUTICS (2019)
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Giulietta Maruggi et al.
MOLECULAR THERAPY (2019)
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
Jiangsheng Xu et al.
NATURE NANOTECHNOLOGY (2019)
Recent therapeutic trends and promising targets in triple negative breast cancer
Soo-Yeon Hwang et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133
Hongran Yin et al.
MOLECULAR THERAPY (2019)
Carrier-Free CXCR4-Targeted Nanoplexes Designed for Polarizing Macrophages to Suppress Tumor Growth
Michael B. Deci et al.
CELLULAR AND MOLECULAR BIOENGINEERING (2019)
Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy
Chunai Gong et al.
JOURNAL OF NANOBIOTECHNOLOGY (2019)
Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles
Anbarasu Kannan et al.
SCIENTIFIC REPORTS (2019)
MicroRNAs Contribute to Breast Cancer Invasiveness
Ivana Fridrichova et al.
CELLS (2019)
Molecular stratification within triple-negative breast cancer subtypes
Dong-Yu Wang et al.
SCIENTIFIC REPORTS (2019)
Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer
Min Woo Kim et al.
THERANOSTICS (2019)
Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer
Charles Sinclair et al.
CANCER RESEARCH (2019)
Tumor-secreted extracellular vesicles promote the activation of cancer-associated fibroblasts via the transfer of microRNA-125b
Luyen Tien Vu et al.
JOURNAL OF EXTRACELLULAR VESICLES (2019)
Antisense oligonucleotides
Daniel R. Scoles et al.
NEUROLOGY-GENETICS (2019)
Advances in mRNA Vaccines for Infectious Diseases
Cuiling Zhang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Emanuela Martino et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Thomas A. Werfel et al.
CANCER RESEARCH (2018)
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
L. Gerratana et al.
CANCER TREATMENT REVIEWS (2018)
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
Zheng Xue et al.
CELL RESEARCH (2018)
Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Recep Bayraktar et al.
CLINICAL CANCER RESEARCH (2018)
AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells
Diana Rafael et al.
DRUG DELIVERY (2018)
MicroRNAs in regulation of triple-negative breast cancer progression
Dominika Piasecka et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model
Walhan Alshaer et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Dendritic Cell-Based Cancer Vaccines
Patricia M. Santos et al.
JOURNAL OF IMMUNOLOGY (2018)
Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer
Wenyan Fu et al.
MOLECULAR IMMUNOLOGY (2018)
Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer
Lina Liu et al.
MOLECULAR THERAPY (2018)
Liposomal Drug Delivery Systems and Anticancer Drugs
Temidayo O. B. Olusanya et al.
MOLECULES (2018)
mRNA vaccines - a new era in vaccinology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
Peijing Zhang et al.
CELL REPORTS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Genetic Markers in Triple-Negative Breast Cancer
Zuzana Sporikova et al.
CLINICAL BREAST CANCER (2018)
An RNA toolbox for cancer immunotherapy
Fernando Pastor et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo
Gonzalo Almanza et al.
SCIENTIFIC REPORTS (2018)
MicroRNA 603 acts as a tumor suppressor and inhibits triplenegative breast cancer tumorigenesis by targeting elongation factor 2 kinase
Recep Bayraktar et al.
ONCOTARGET (2017)
Dysregulation of microRNAs in triple-negative breast cancer
Sylwia Paszek et al.
GINEKOLOGIA POLSKA (2017)
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies
Carsten Denkert et al.
LANCET (2017)
Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors
Zilan Zhou et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Antibody fragments as nanoparticle targeting ligands: a step in the right direction
Daniel A. Richards et al.
CHEMICAL SCIENCE (2017)
Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells
KeeSoo Nam et al.
ONCOTARGET (2017)
Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity
John J. Suschak et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA
Radu Mihaila et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems
Anish Babu et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2017)
Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review
Mingfang Wang et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Global Cancer in Women: Burden and Trend
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Imaging-guided delivery of RNAi for anticancer treatment
Junqing Wang et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells
Manoj B. Parmar et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2016)
Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy
Aarohi Bhargava-Shah et al.
NANOMEDICINE (2016)
Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy
Shengpeng Wang et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells
Hanna Taipaleenmaeki et al.
ONCOTARGET (2016)
ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer
Peng Guo et al.
THERANOSTICS (2016)
Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy
Maneesh Gujrati et al.
Advanced Healthcare Materials (2016)
18F-FDG PET/CT for Monitoring the Response of Breast Cancer to miR-143-Based Therapeutics by Targeting Tumor Glycolysis
Ying Miao et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Combination of microRNA therapeutics with small-molecule anticancer drugs: Mechanism of action and co-delivery nanocarriers
Xin Dai et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association
Eunjung Lee et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Lentiviral vector-mediated doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative breast cancer cells
Shihai Liu et al.
ONCOLOGY REPORTS (2015)
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity
Keith O'Brien et al.
ONCOTARGET (2015)
RNA-Based Vaccines in Cancer Immunotherapy
Megan A. McNamara et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
siRNA Versus miRNA as Therapeutics for Gene Silencing
Jenny K. W. Lam et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
Vandana G. Abramson et al.
CANCER (2015)
Polymeric micelles for oral drug administration enabling locoregional and systemic treatments
Susana M. N. Simoes et al.
EXPERT OPINION ON DRUG DELIVERY (2015)
Systematic review of catalyst nanoparticles synthesized by solution process: towards efficient carbon nanotube growth
Mohd Asyadi Azam et al.
JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY (2015)
Nanoemulsion: an advanced mode of drug delivery system
Manjit Jaiswal et al.
3 BIOTECH (2015)
Hyaluronic acid-chitosan nanoparticles for co-delivery of M1R-34a and doxorubicin in therapy against triple negative breast cancer
Xiongwei Deng et al.
BIOMATERIALS (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Polymeric Micelle Assembly for Preparation of Large-Sized Mesoporous Metal Oxides with Various Compositions
Bishnu Prasad Bastakoti et al.
LANGMUIR (2014)
Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment
Manju Saraswathy et al.
MATERIALS TODAY (2014)
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
Luca F. R. Gebert et al.
NUCLEIC ACIDS RESEARCH (2014)
Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy
Varun Kumar et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2014)
Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
R. Joseph Bender et al.
PLOS ONE (2013)
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
John Stagg et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2013)
Safety profile of RNAi nanomedicines
Scott A. Barros et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
RNA interference in mammals: behind the screen
Eric Campeau et al.
BRIEFINGS IN FUNCTIONAL GENOMICS (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
Delivery of siRNA Therapeutics: Barriers and Carriers
Jie Wang et al.
AAPS JOURNAL (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
分享论文
